Advanced NSCLC in Focus: Collaborative Management of EGFR Mutation and ALK Rearrangement Disease
Danny Nguyen, MD; Katherine Cunha, MSN, FNP-C; Michelle Munroe, APRN; and Jun Zhang, MD, PhD, discuss how to optimize treatment selection and manage adverse events in patients with advanced non–small cell lung cancer (NSCLC) with EGFR mutations and ALK rearrangements, emphasizing collaborative care strategies, patient education, and proactive adverse effect management to maintain treatment adherence and quality of life.
EP. 1: Clinical Case: EGFR-Mutant (Exon 19 del) Advanced NSCLC
June 25th 2025Panelists discuss how a 46-year-old graphic designer with stage IV EGFR-mutant non–small cell lung cancer and brain metastases was successfully treated with amivantamab plus lazertinib after weighing multiple frontline treatment options.
EP. 2: The Treatment Landscape For Advanced EGFR-Mutant NSCLC
June 25th 2025Panelists discuss how the treatment landscape for EGFR-mutant non–small cell lung cancer has evolved to include 3 viable frontline options (osimertinib alone, osimertinib plus chemotherapy, and amivantamab plus lazertinib), with treatment selection based on patient characteristics, preferences, and physician judgment rather than a strict algorithmic approach.
